"It seems like this past week has been quite challenging for you," a disembodied voice tells me, before proceeding to ask a series of increasingly personal questions. "Have you been feeling down or depressed?" "Can you describe what this feeling has been like for you?" "Does the feeling lift at all when something good happens?" When I respond to each one, my chatbot interviewer thanks me for my honesty and empathises with any issues. By the end of the conversation, I will have also spoken about my sleep patterns, sex drive and appetite for food.

Early forecasting of individual cognitive decline in Alzheimer's disease (AD) is central to disease evaluation and management. Despite advances, it is as of yet challenging for existing methodological frameworks to integrate multimodal data for longitudinal personalized forecasting while maintaining interpretability. To address this gap, we present the Neural Koopman Machine (NKM), a new machine learning architecture inspired by dynamical systems and attention mechanisms, designed to forecast multiple cognitive scores simultaneously using multimodal genetic, neuroimaging, proteomic, and demographic data. NKM integrates analytical ($α$) and biological ($β$) knowledge to guide feature grouping and control the hierarchical attention mechanisms to extract relevant patterns. By implementing Fusion Group-Aware Hierarchical Attention within the Koopman operator framework, NKM transforms complex nonlinear trajectories into interpretable linear representations. To demonstrate NKM's efficacy, we applied it to study the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. Our results suggest that NKM consistently outperforms both traditional machine learning methods and deep learning models in forecasting trajectories of cognitive decline. Specifically, NKM (1) forecasts changes of multiple cognitive scores simultaneously, (2) quantifies differential biomarker contributions to predicting distinctive cognitive scores, and (3) identifies brain regions most predictive of cognitive deterioration. Together, NKM advances personalized, interpretable forecasting of future cognitive decline in AD using past multimodal data through an explainable, explicit system and reveals potential multimodal biological underpinnings of AD progression.

Understanding the dynamic reorganization of brain networks is critical for predicting cognitive decline, neurological progression, and individual variability in clinical outcomes. This work proposes a multimodal graph neural network framework that integrates structural MRI, diffusion tensor imaging, and functional MRI to model spatiotemporal brain network reorganization. Brain regions are represented as nodes and structural and functional connectivity as edges, forming longitudinal brain graphs for each subject. Temporal evolution is captured via fractional stochastic differential operators embedded within graph-based recurrent networks, enabling the modeling of long-term dependencies and stochastic fluctuations in network dynamics. Attention mechanisms fuse multimodal information and generate interpretable biomarkers, including network energy entropy, graph curvature, fractional memory indices, and modality-specific attention scores. These biomarkers are combined into a composite prognostic index to quantify individual risk of network instability or cognitive decline. Experiments on longitudinal neuroimaging datasets demonstrate both predictive accuracy and interpretability. The results highlight the potential of mathematically rigorous, multimodal graph-based approaches for deriving clinically meaningful biomarkers from existing imaging data without requiring new data collection.

Patients with rare neurological diseases report cognitive symptoms--"brain fog"--invisible to traditional tests. Proof-of-concept in phenylketonuria (PKU) shows speech-derived "Proficiency in Verbal Discourse" correlates Success would transform episodic neurology into continuous personalized monitoring for millions globally. In phenylketonuria (PKU), adults describe "brain fog" and working memory deficits [ We envision smartphone-based speech analysis integrated with medical databases via RELGT, enabling continuous neurocog-nitive monitoring--transforming reactive episodic care into proactive precision neurology. Parkinson's disease involves hypophonia and speech fluctuations tied to medication Huntington's disease reflects CAG-repeat-driven degrneration and progressive motor-cognitive decline. Wilson's disease presents with dysarthria linked to copper accumulation.

Chronic diseases often progress differently across patients. Rather than randomly varying, there are typically a small number of subtypes for how a disease progresses across patients. To capture this structured heterogeneity, the Subtype and Stage Inference Event-Based Model (SuStaIn) estimates the number of subtypes, the order of disease progression for each subtype, and assigns each patient to a subtype from primarily cross-sectional data. It has been widely applied to uncover the subtypes of many diseases and inform our understanding of them. But how robust is its performance? In this paper, we develop a principled Bayesian subtype variant of the event-based model (BEBMS) and compare its performance to SuStaIn in a variety of synthetic data experiments with varied levels of model misspecification. BEBMS substantially outperforms SuStaIn across ordering, staging, and subtype assignment tasks. Further, we apply BEBMS and SuStaIn to a real-world Alzheimer's data set. We find BEBMS has results that are more consistent with the scientific consensus of Alzheimer's disease progression than SuStaIn.

Biomarker discovery from high-throughput transcriptomic data is crucial for advancing precision medicine. However, existing methods often neglect gene-gene regulatory relationships and lack stability across datasets, leading to conflation of spurious correlations with genuine causal effects. To address these issues, we develop a causal graph neural network (Causal-GNN) method that integrates causal inference with multi-layer graph neural networks (GNNs). The key innovation is the incorporation of causal effect estimation for identifying stable biomarkers, coupled with a GNN-based propensity scoring mechanism that leverages cross-gene regulatory networks. Experimental results demonstrate that our method achieves consistently high predictive accuracy across four distinct datasets and four independent classifiers. Moreover, it enables the identification of more stable biomarkers compared to traditional methods. Our work provides a robust, efficient, and biologically interpretable tool for biomarker discovery, demonstrating strong potential for broad application across medical disciplines.

Clinical practitioners use all available data modalities for diagnosing and treating eye diseases like Diabetic Retinopathy (DR) or Diabetic Macular Edema (DME).

Neurodevelopmental disorders such as Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD) are characterized by disrupted cortical oscillatory activity, particularly in the alpha and gamma frequency bands. These abnormalities are linked to deficits in attention, sensory processing, and cognitive function. In this work, we present an adaptive machine learning-based brain-computer interface (BCI) system designed to modulate neural oscillations through frequency-specific auditory stimulation to enhance cognitive readiness in individuals with FXS. EEG data were recorded from 38 participants using a 128-channel system under a stimulation paradigm consisting of a 30-second baseline (no stimulus) followed by 60-second auditory entrainment episodes at 7Hz, 9Hz, 11Hz, and 13Hz. A comprehensive analysis of power spectral features (Alpha, Gamma, Delta, Theta, Beta) and cross-frequency coupling metrics (Alpha-Gamma, Alpha-Beta, etc.) was conducted. The results identified Peak Alpha Power, Peak Gamma Power, and Alpha Power per second per channel as the most discriminative biomarkers. The 13Hz stimulation condition consistently elicited a significant increase in Alpha activity and suppression of Gamma activity, aligning with our optimization objective. A supervised machine learning framework was developed to predict EEG responses and dynamically adjust stimulation parameters, enabling real-time, subject-specific adaptation. This work establishes a novel EEG-driven optimization framework for cognitive neuromodulation, providing a foundational model for next-generation AI-integrated BCI systems aimed at personalized neurorehabilitation in FXS and related disorders.